No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up

References

• Puhan MA, Van Natta ML, Palella FJ, et al. Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin Infect Dis. 2010;51(8):947–956.
   PubMed Web of Science ®Google Scholar
• Nou E, Lo J, Grinspoon SK. Inflammation, immune activation and cardiovascular disease in HIV. AIDS. 2016;30(10):1495–1509.
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Hanna DB, Kizer JR. Recent insights into cardiovascular disease (CVD) risk among HIV-infected adults. Curr HIV/AIDS Rep. 2016;13(1):44–52.
   PubMed Web of Science ®Google Scholar
• Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117(2):214–220.
   PubMed Web of Science ®Google Scholar
• Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384(9939):241–248.
   PubMed Web of Science ®Google Scholar
• Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–2512.
   PubMed Web of Science ®Google Scholar
• Kearns A, Gordon J, Burdo T, et al. HIV-1-associated atherosclerosis: unraveling the missing link. J Am Coll Cardiol. 2017;69(25):3084–3098.
   PubMed Web of Science ®Google Scholar
• Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
   PubMed Web of Science ®Google Scholar
• INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
   PubMed Web of Science ®Google Scholar
• DAD Study Group, Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–1735.
   PubMed Web of Science ®Google Scholar
• Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–F24.
   PubMed Web of Science ®Google Scholar
• Elion RA, Althoff KN, Zhang J, et al. Recent abacavir use increases risk of type 1 and type 2 myocardial infarctions among adults with HIV. J Acquir Immune Defic Syndr. 2018;78(1):62–72.
   PubMed Web of Science ®Google Scholar
• Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018;5(6):e291–e300.
   PubMed Web of Science ®Google Scholar
• Maggi P, Perilli F, Lillo A, et al. Rapid progression of carotid lesions in HAART-treated HIV-1 patients. Atherosclerosis. 2007;192(2):407–412.
   PubMed Web of Science ®Google Scholar
• Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. 2008;196(2):720–726.
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-media thickness measurements from the FRAM study. AIDS. 2009;23(14):1841–1849.
   PubMed Web of Science ®Google Scholar
• Calza L, Verucchi G, Pocaterra D, et al. Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. Int J STD AIDS. 2009;20(10):683–689.
   PubMed Web of Science ®Google Scholar
• Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109(13):1603–1608.
   PubMed Web of Science ®Google Scholar
• Mercié P, Thiébaut R, Aurillac-Lavignolle V, et al. Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med. 2005;6:380–387.
   PubMed Web of Science ®Google Scholar
• Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS. 2005;19(9):927–933.
   PubMed Web of Science ®Google Scholar
• Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118(2):e29–e35.
   PubMedGoogle Scholar
• Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS. 2010;24(6):789–802.
   PubMed Web of Science ®Google Scholar
• Yombi JC, Pozniak AL. Is it time for integrase inhibitors to be the preferred regimen for the first-line treatment of HIV-1-infected naive patients? AIDS Rev. 2016;18(2):89–100.
   PubMed Web of Science ®Google Scholar
• Psichogiou M, Poulakou G, Basoulis D, et al. Recent advances in antiretroviral agents: potent integrase inhibitors. Curr Pharm Des. 2017;23(18):2552–2567.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129(25 Suppl 2):S1–S45.
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–1701.
   PubMed Web of Science ®Google Scholar
• Volpe GE, Tang AM, Polak JF, et al. Progression of carotid intima-media thickness and coronary artery calcium over 6 years in an HIV-infected cohort. J Acquir Immune Defic Syndr. 2013;64(1):51–57.
   PubMed Web of Science ®Google Scholar
• Godoi ET, Brandt CT, Lacerda HR, et al. Intima-media thickness in the carotid and femoral arteries for detection of arteriosclerosis in human immunodeficiency virus-positive individuals. Arq Bras Cardiol. 2017;108(1):3–11.
   PubMed Web of Science ®Google Scholar
• Sun D, Wu Y, Yuan Y, et al. Is the atherosclerotic process accentuated under conditions of HIV infection, antiretroviral therapy, and protease inhibitor exposure? Meta-analysis of the markers of arterial structure and function. Atherosclerosis. 2015;242(1):109–116.
   PubMed Web of Science ®Google Scholar
• Maggi P, Bellacosa C, Leone A, et al. Cardiovascular risk in advanced naive HIV-infected patients starting antiretroviral therapy: comparison of three different regimens – PREVALEAT II cohort. Atherosclerosis. 2017;263:398–404.
   PubMed Web of Science ®Google Scholar
• Stein JH, Ribaudo HJ, Hodis HN, et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015;29(14):1775–1783.
   PubMed Web of Science ®Google Scholar
• Delaney JA, Scherzer R, Biggs ML, et al. Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS. 2010;24(14):2201–2209.
   PubMed Web of Science ®Google Scholar
• Kovari H, Calmy A, Doco-Lecompte T, et al. Antiretroviral drugs associated with subclinical coronary artery disease in the Swiss HIV Cohort Study. Clin Infect Dis. [cited 2019 Apr 8]. DOI:10.1093/cid/ciz283
   Google Scholar
• Thomas GP, Li X, Post WS, et al. Associations between antiretroviral use and subclinical coronary atherosclerosis. AIDS. 2016;30(16):2477–2486.
   PubMed Web of Science ®Google Scholar
• Jean M, Saada M, Collin F, et al. Prevalence and factors associated with discordant intima-media thickness and arterial stiffness combined measurements in people living with HIV. Infect Dis. 2016;48(11–12):857–859.
   PubMed Web of Science ®Google Scholar
• Knudsen A, Malmberg CAE, Kjaer A, et al. Low prevalence of peripheral arterial disease in a cross-sectional study of Danish HIV-infected patients. Infect Dis. 2015;47(11):776–782.
   PubMed Web of Science ®Google Scholar